55 Cambridge Parkway, Suite 103
About Anthos Therapeutics
Anthos Therapeutics, Inc., a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.
Anthos' priority R&D program is abelacimab, a potent biologic molecule designed to achieve profound Factor XI suppression through dual activity against the active form (Factor XIa) and its precursor (Factor XI). Created for the heterogeneous real world, abelacimab has the promise of suitability for a broad spectrum of patients, no requirement for dosage adjustment in cases of renal or hepatic impairment and no interactions with other drugs. It is planned to be available as a rapid-onset intravenous presentation to prevent VTEs in the hospital setting and a once-monthly subcutaneous version for ongoing stroke prevention in the community, with the assurance of improved adherence.
More than 1 in 4 people worldwide continue to die from thromboembolic events 1,2 – a death toll due in part to the widespread underutilization, under-dosing and early discontinuation of anticoagulation, with as many as 50% of eligible patients entirely untreated.3,4 While some controlled clinical studies with DOACs in tightly defined trial populations have shown improvements in the bleeding risk, this risk remains a strong deterrent to optimal prescribing in routine practice. This underuse of conventional anticoagulants, including DOACs, stems from the fact that they all impact physiological hemostasis as well as pathological thrombosis, forcing prescribers in the real world – where patients are often frail, elderly and encumbered with co-morbidities – to walk a tightrope every time, weighing up the serious risk of lethal or life-changing thromboembolic events with the ominous threat of bleeding.
In light of this stalemate, the time has come for a paradigm shift. New scientific understanding shows that taking aim at an entirely new target, Factor XI (and its activated counterpart Factor XIa), could enable pharmacological ‘uncoupling' of the physiological hemostasis and pathological thrombosis pathways. Through transformative hemostasis-sparing anticoagulation, a new class of Factor XI inhibitors could potentially fulfill the ultimate ambition of vital protection from thromboembolic events whilst reducing the hazard of a clinically significant bleeding risk, giving physicians the confidence to prescribe to many more people and enabling a meaningful reduction in the human and socioeconomic burden of thrombotic disease.
1. Wendelboe AM, Raskob GE. Circ Res 2016; 118, 1340–1347. 2. Editorial. Lancet Haematology 2015, Vol 2, e393 3. Piccini JP et al. Circulation. 2019;139:1497–1506. 4. Alamneh EA et al. Am J Cardiovasc Drugs 2016; 16:183–200.
26 articles about Anthos Therapeutics
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or CRNM Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced during a Late-Breaking session of the American Heart Association meeting that abelacimab demonstrated a highly significant reduction in bleeding events across all primary and secondary endpoints versus a standard of care direct-oral anticoagulant.
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Anthos Therapeutics, Inc. announced that primary data from the AZALEA-TIMI 71 study of patients with atrial fibrillation at moderate-to-high risk of stroke has been selected for a Late Breaking session at the American Heart Association Scientific Sessions 2023, being held November 11-13 in Philadelphia.
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced that the AZALEA-TIMI 71 Phase 2 study in 1,287 patients with atrial fibrillation at moderate-to-high risk of stroke, met its primary endpoint.
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
Anthos Therapeutics presented new data in collaboration with two internationally recognized patient advocacy groups, detailing the impacts of patient-relevant bleeding on individuals prescribed anticoagulants.
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced two important regulatory milestones in China and Japan for clinical trials of the company’s investigational agent, abelacimab.
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
Anthos Therapeutics presented details of the development of a novel patient-reported outcome assessment scale to measure the patient relevant burden of oral anticoagulant treatment at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.
Anthos Therapeutics announced the Company will present four posters at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
Anthos Therapeutics today announced that it has enrolled the first patient in LILAC-TIMI 76, a Phase 3 study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation (AF) deemed unsuitable for current anticoagulants by their physician.
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
Anthos Therapeutics oday announced the initiation of recruitment for its second Phase 3 clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa.
Anthos Therapeutics, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK.
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Anthos Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational Factor XI inhibitor, abelacimab, for the treatment of thrombosis associated with cancer.
Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that it will participate in the 2022 BIO International Convention occurring at the San Diego Convention Center from June 13 – 16.
Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of Drew Young as Chief Commercial Officer and Head of Patient Experience.
Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced that the first patient had been enrolled in a phase 3 clinical trial investigating a Factor XI agent.
1/10/2022BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
1/7/2022With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer.